MED MEDIFAST INC
Price Chart
Executive Summary
Medifast filed an 8-K reporting stockholder approval of an amended share incentive plan and the formal appointment of Nicholas Johnson as CEO, effective June 1, 2026, succeeding Dan Chard who stays as non-executive Chairman. The plan adds 250,000 shares for equity awards, and Johnson's compensation includes a $600,000 base salary, 100% target bonus, and 250% LTI target. The transition was pre-announced in January and is orderly.
Actionable Insight
Orderly leadership transition removes near-term governance overhang. Monitor the next quarterly earnings (due August) for any strategic shifts under new CEO or changes in coach-led model performance. The share plan increase is standard and unlikely to materially dilute.
Key Facts
- Stockholders approved Amended and Restated 2012 Share Incentive Plan, increasing authorized shares by 250,000 to approximately 1,425,000 shares.
- Nicholas Johnson appointed CEO effective June 1, 2026; Dan Chard transitions to non-executive Chairman.
- Johnson's compensation: $600,000 base salary, 100% target bonus, 250% LTI target (69% total comp increase).
- All seven director nominees were elected; RSM US LLP ratified as auditor; say-on-pay and share plan approved.
- CEO transition was disclosed in a prior 8-K on January 5, 2026; departure not due to disagreements.
Financial Impact
None directly. The share plan increase enables future equity grants but the number (250K shares) is modest relative to market cap (~$140M). CEO compensation increase is routine for promotion.
Risk Factors
- Potential future dilution from equity grants under the new share plan.
- Execution risk under new CEO in a highly competitive metabolic health market.
- Bearish analyst consensus (0% buy, 8 sell/strong sell) suggests low market confidence in near-term fundamentals.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-038109 |
| Document: med-20260519.htm | 0001628280-26-038109 |
| Document: pressrelease-nickjohnsonceo.htm | 0001628280-26-038109 |
| Document: nickjohnson_promotionlette.htm | 0001628280-26-038109 |
| Document: 0001628280-26-038109-index-headers.html | 0001628280-26-038109 |
| Document: 0001628280-26-038109-index.html | 0001628280-26-038109 |
| Document: 0001628280-26-038109.txt | 0001628280-26-038109 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
19d ago
|
8-K
| $12.70 $12.10 | ▼ −4.72% | ▼ −1.97% | $11.25 (−11.42%) |
|
May 26, 2026
25d ago
|
8-K
| $12.72 $12.36 | ▼ −2.83% | ▼ −4.04% | $11.25 (−11.56%) |
|
May 21, 2026
4w ago
|
Press Release
| $12.63 $12.53 | ▼ −0.79% | ▼ −2.64% | $11.25 (−10.93%) |
|
May 21, 2026
4w ago
|
Press Release
| $12.63 $12.53 | ▼ −0.79% | ▼ −2.64% | $11.25 (−10.93%) |
|
May 15, 2026
5w ago
|
Press Release
| $12.48 $12.59 | ▲ +0.88% | ▼ −0.08% | $11.25 (−9.86%) |
|
May 15, 2026
5w ago
|
Press Release
| $12.48 $12.59 | ▲ +0.88% | ▼ −0.08% | $11.25 (−9.86%) |
|
May 4, 2026
6w ago
|
8-K
| $13.02 $12.57 | ▲ +3.46% | ▲ +5.44% | $11.25 (+13.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access